Skip to main content

Table 1 Baseline characteristics of the patients

From: Association between viscoelastic tests-guided therapy with synthetic factor concentrates and allogenic blood transfusion in liver transplantation: a before-after study

 

Unmatched Cohort (n = 237)

Matched Cohort (n = 135)b

 

Intervention (n = 54)

Control (n = 183)

p valuea

Intervention (n = 46)

Control (n = 89)

p valuea

Baseline characteristics and co-morbidities

 Age, years

53.0 ± 11.1

51.9 ± 12.0

0.550

53.0 ± 11.8

52.5 ± 11.9

0.791

 Gender, male

43 / 54 (79.6)

131 / 183 (71.6)

0.239

35 / 46 (76.1)

71 / 89 (79.8)

0.620

 Weight, kg

77.8 ± 15.9

76.0 ± 17.0

0.483

76.2 ± 16.5

76.7 ± 15.7

0.867

 Height, cm

171.2 ± 8.0

168.3 ± 9.9

0.051

170.2 ± 7.8

170.1 ± 8.6

0.927

 BMI, kg/m2

26.6 ± 4.4

26.7 ± 5.1

0.848

26.3 ± 4.6

26.4 ± 4.6

0.945

 Co-morbidities

 Chronic kidney disease

3 / 54 (5.6)

34 / 183 (18.6)

0.020

2 / 46 (4.3)

17 / 89 (19.1)

0.019

 Hypertension

14 / 54 (25.9)

31 / 183 (16.9)

0.139

13 / 46 (28.3)

14 / 89 (15.7)

0.084

 Diabetes mellitus

11 / 54 (20.4)

48 / 183 (26.2)

0.381

9 / 46 (19.6)

28 / 89 (31.5)

0.141

Etiology of liver disease

0.578

  

0.852

 Budd-Chiari

0 / 54 (0.0)

3 / 182 (1.6)

 

0 / 46 (0.0)

1 / 89 (1.1)

 

 Alcohol

14 / 54 (25.9)

32 / 182 (17.6)

 

11 / 46 (23.9)

22 / 89 (24.7)

 

 Hepatitis C

23 / 54 (42.6)

89 / 182 (48.9)

 

19 / 46 (41.3)

40 / 89 (44.9)

 

 Hepatitis B

2 / 54 (3.7)

13 / 182 (7.1)

 

2 / 46 (4.3)

8 / 89 (9.0)

 

 Cryptogenic

5 / 54 (9.3)

16 / 182 (8.8)

 

4 / 46 (8.7)

6 / 89 (6.7)

 

 PSC

2 / 54 (3.7)

6 / 182 (3.3)

 

2 / 46 (4.3)

2 / 89 (2.2)

 

 Autoimmune hepatitis

2 / 54 (3.7)

6 / 182 (3.3)

 

2 / 46 (4.3)

3 / 89 (3.4)

 

 FAP

0 / 54 (0.0)

5 / 182 (2.7)

 

0 / 46 (0.0)

0 / 89 (0.0)

 

 Acute Liver Failure

0 / 54 (0.0)

2 / 182 (1.1)

 

0 / 46 (0.0)

1 / 89 (1.1)

 

 Others

6 / 54 (11.1)

10 / 182 (5.5)

 

6 / 46 (13.0)

6 / 89 (6.7)

 

Clinical status pre-transplantation

 Use of mechanical ventilation

2 / 54 (3.7)

14 / 183 (7.7)

0.309

2 / 46 (4.3)

6 / 89 (6.7)

0.576

 Use of hemodialysis

4 / 54 (7.4)

16 / 183 (8.7)

0.756

3 / 46 (6.5)

7 / 89 (7.9)

0.777

 Previous surgery

8 / 54 (14.8)

37 / 183 (20.2)

0.373

8 / 46 (17.4)

14 / 89 (15.7)

0.804

 Child-Pugh classification

0.019

  

0.223

 A

13 / 54 (24.1)

44 / 183 (24.0)

 

13 / 46 (28.3)

17 / 89 (19.1)

 

 B

7 / 54 (13.0)

57 / 183 (31.1)

 

7 / 46 (15.2)

24 / 89 (27.0)

 

 C

34 / 54 (63.0)

82 / 183 (44.8)

 

26 / 46 (56.5)

48 / 89 (53.9)

 

 MELD score

22.7 ± 8.8

21.6 ± 8.2

0.418

21.9 ± 9.2

22.0 ± 7.9

0.954

 Re-transplantation

1 / 54 (1.9)

0 / 183 (0.0)

0.065

1 / 46 (2.2)

0 / 89 (0.0)

0.162

Complications

 Encephalopathy

1 / 54 (1.9)

94 / 183 (51.4)

< 0.001

1 / 46 (2.2)

50 / 89 (56.2)

< 0.001

 Upper digestive hemorrhage

1 / 54 (1.9)

67 / 183 (36.6)

< 0.001

1 / 46 (2.2)

37 / 89 (41.6)

< 0.001

 Portal vein thrombosis

4 / 54 (7.4)

10 / 183 (5.5)

0.594

3 / 46 (6.5)

4 / 89 (4.5)

0.614

 Portopulmonary hypertension

1 / 54 (1.9)

4 / 183 (2.2)

0.880

1 / 46 (2.2)

2 / 89 (2.2)

0.978

 HCC

23 / 54 (42.6)

53 / 183 (29.0)

0.059

16 / 46 (34.8)

28 / 89 (31.5)

0.696

 Ascites

  

0.082

   

 Controlled

13 / 54 (24.1)

37 / 183 (20.2)

 

12 / 46 (26.1)

26 / 89 (29.2)

0.083

 Refractory

14 / 54 (25.9)

78 / 183 (42.6)

 

11 / 46 (23.9)

35 / 89 (39.3)

 

Medications in use

 Furosemide

22 / 54 (40.7)

53 / 183 (29.0)

0.101

20 / 46 (43.5)

27 / 89 (30.3)

0.128

 Spironolactone

27 / 54 (50.0)

68 / 183 (37.2)

0.013

23 / 46 (50.0)

37 / 89 (41.6)

0.350

 Propranolol

27 / 54 (50.0)

58 / 183 (31.7)

0.090

22 / 46 (47.8)

33 / 89 (37.1)

0.228

Pre-transplantation laboratory tests

 INR

1.8 ± 0.8

1.7 ± 0.6

0.113

1.8 ± 0.8

1.7 ± 0.7

0.532

 Total bilirubin, mg/dL

5.4 ± 8.0

6.2 ± 8.1

0.532

4.8 ± 7.6

7.2 ± 9.6

0.149

 Albumin, g/dL

3.2 ± 0.5

3.0 ± 0.6

0.025

3.3 ± 0.5

3.0 ± 0.6

0.004

 Hemoglobin, g/dL

11.3 ± 2.5

11.3 ± 2.6

0.641

11.3 ± 2.7

10.9 ± 2.5

0.433

 Hematocrit, %

32.5 ± 7.0

32.5 ± 7.5

0.954

32.6 ± 7.4

31.9 ± 7.4

0.633

 Fibrinogen, mg/dL

214.5 ± 92.6

178.3 ± 94.5

0.301

214.5 ± 92.6

153.7 ± 70.2

0.095

 Platelets, × 1000/mm3

80.5 ± 59.2

74.2 ± 55.0

0.473

81.6 ± 62.7

67.1 ± 48.7

0.143

 Urea, mg/dL

36.5 ± 15.7

49.7 ± 43.3

0.030

35.9 ± 14.9

51.9 ± 47.8

0.028

 Creatinine, mg/dL

0.9 ± 0.4

1.2 ± 0.8

0.004

0.9 ± 0.4

1.2 ± 0.7

0.008

 Sodium, mEq/L

137.1 ± 3.3

137.5 ± 5.8

0.702

137.3 ± 3.0

137.4 ± 6.1

0.963

 Potassium, mEq/L

4.3 ± 0.5

4.1 ± 0.5

0.074

4.3 ± 0.5

4.2 ± 0.5

0.316

 Ejection fraction of LV, %

66.2 ± 8.5

67.0 ± 7.3

0.577

66.4 ± 8.9

68.3 ± 6.6

0.253

  1. Kg: kilograms; cm: centimeters; BMI: body mass index; PSC: Primary Sclerosing Cholangitis; MELD: Model for End-Stage Liver Disease; FAP: Familial Amyloid Polyneuropathy; INR: international normalized ratio; mg: miligrams; dL; deciliters; g: grams; HCC: hepatocellular carcinoma; LV: left ventricle
  2. Data presented as mean ± standard deviation or number / total (percentage)
  3. aComparison of differences between the two groups using the t test for continuous variables and the χ2 test for categorical variables
  4. bAdjusted by age, Child, MELD, presence of HCC and pre-transplantation hemoglobin
Back to article page

BMC Anesthesiology

ISSN: 1471-2253

Contact us